Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

RESPILIQ - enteral CO2 absorption for the therapy of hypercapnic lung failure

Project description

Enhancing survival and quality of life of CO2-impaired patients

Hypercapnia refers to a dangerous build-up of CO2 in the blood. It affects millions of people, including premature babies, intensive care unit patients with lung failure and those with chronic obstructive pulmonary disease. Current treatments often fall short in treating this condition. The EIC-funded RESPILIQ project aims to revolutionise therapy and significantly improve survival. Instead of tackling the problem via the lungs, researchers will use the human gut as a respiratory organ, leveraging its natural ability to exchange CO2. Administered orally or rectally, it binds CO2 in the intestinal fluid and safely removes it, reducing blood CO2 levels. The proposed research aims to improve survival rates and dramatically enhance the quality of life for those suffering from hypercapnia.

Objective

Premature babies and patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO2 in the blood. In Europe alone there are around 1.8M people. Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of COPD, which has not yet been adequately solved. Our goal is to revolutionize therapy and significantly improve survival and, above all, the quality of life of these large patient groups suffering from hypercapnia. Instead of tackling the
problem via the lungs, RESPILIQ uses the human gut as a respiratory organ. The intestine forms a highly effective exchange membrane for carbon dioxide (CO2). In the gut, RESPILIQ can bind CO2 from the intestinal fluid and excrete it via naturalis. Administered orally or rectally, RESPILIQ initiates a life-saving reduction of pCO2 in the blood

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

O11 BIOMEDICAL GMBH
Net EU contribution
€ 2 499 999,00
Address
SCHLOSSPARKSTR. 93
52072 Aachen
Germany
SME
Yes
Region
Nordrhein-Westfalen Köln Städteregion Aachen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 603 638,83